natgillin/translations-raw huggingface dataset:
Samtidig administration af EVOTAZ og disse antiepileptika er kontraindiceret (se pkt. 
Co-administration of EVOTAZ and these antiepileptics is contraindicated (see section 4.3).
4.3 og 4.5), da plasmakoncentrationer af atazanavir reduceres på grund af induktion af CYP3A4, og derudover kan reducerede plasmakoncentrationer af cobicistat medføre plasmaniveauer af cobicistat, som er utilstrækkelige til at opnå fornøden farmakoforstærkning af atazanavir. 
Co-administration of EVOTAZ and medicinal products that induce CYP3A4 is contraindicated or not recommended (see sections 4.3 and 4.5) because, in addition to decreased plasma concentrations of atazanavir due to induction of CYP3A4, decreased plasma concentrations of cobicistat could result in cobicistat plasma levels that are insufficient to achieve adequate pharmacoenhancement of atazanavir.
Se produktresuméet for cobicistat for yderligere oplysninger. 
For more information consult the cobicistat Summary of Product Characteristics.
(atazanavir 300 mg 1 gang dagligt og cobicistat 150 mg 1 gang dagligt) 
(atazanavir 300 mg once daily with cobicistat 150 mg once daily)
4.5) sildenafil - når det anvendes til behandling af pulmonal arteriel hypertension (se pkt. 
Sildenafil, when used for the treatment of pulmonary arterial hypertension, is contraindicated (see section 4.3).
EVENTUELLE SÆRLIGE FORHOLDSREGLER VED BORTSKAFFELSE AF IKKE 
Specific dosing recommendations are not
Cobicistat, som er et af indholdsstofferne i EVOTAZ, reducerer den estimerede kreatininclearance på grund af hæmning af den tubulære sekretion af kreatinin. 
Cobicistat, a component of EVOTAZ, has been shown to decrease estimated creatinine clearance due to inhibition of tubular secretion of creatinine.
Cobicistat er en kraftig mekanisme-baseret CYP3A-hæmmer og et CYP3A-substrat. 
Cobicistat is a strong mechanism-based CYP3A inhibitor and is a CYP3A substrate.
I modsætning til ritonavir er cobicistat ikke en CYP1A2-, CYP2B6-, CYP2C8-, CYP2C9-, CYP2C19eller UGT1A1-induktor. 
Unlike ritonavir, cobicistat is not an inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or UGT1A1.
KARDIOVASKULÆRE MIDLER 
CARDIOVASCULAR AGENTS
Sådan skal du tage EVOTAZ 
How to take EVOTAZ
Efavirenz 600 mg som enkeltdosis (cobicistat 150 mg 1 gang dagligt) 
Efavirenz 600 mg single dose (cobicistat 150 mg once daily)
På grund af risiko for både overførsel af hiv samt risiko for alvorlige bivirkninger hos ammede spædbørn, bør mødre informeres om ikke at amme, hvis de får EVOTAZ. 
Studies in animals have been shown excretion of cobicistat/metabolites in milk Because of both the potential for HIV transmission and the potential for serious adverse reactions in breast-feeding infants, women should be instructed not to breast-feed if they are receiving EVOTAZ.
Drospirenon/ethinylestradiol 3 mg/0,02 mg enkeltdosis (atazanavir 300 mg 1 gang dagligt med cobicistat 150 mg 1 gang dagligt) 
Drospirenone/ethinyloestradiol 3 mg/0.02 mg single dose (atazanavir 300 mg once daily with cobicistat 150 mg once daily)
Dosisjustering er ikke nødvendig ved samtidig administration af methadon og EVOTAZ. 
No dosage adjustment is necessary if methadone is co-administered with EVOTAZ.
Da atazanavir er et af indholdsstofferne i EVOTAZ, frarådes kombinationen af EVOTAZ og atorvastatin (se pkt. 
Because atazanavir is a component of EVOTAZ, the combination of EVOTAZ with atorvastatin is not recommended (see section 4.5).
Samtidig administration af EVOTAZ og lægemidler, der hæmmer CYP3A kan resultere i øget plasmakoncentration af atazanavir og/eller cobicistat. 
Co-administration of EVOTAZ with medicinal products that inhibit CYP3A may result in increased plasma concentration of atazanavir and/or cobicistat.
Samtidig administration af EVOTAZ med glecaprevir/pibrentasvir i fastdosiskombination er kontraindiceret på grund af den potentielle forøgelse i risiko for ALAT-stigninger grundet en signifikant stigning i plasmakoncentrationerne af glecaprevir og pibrentasvir (se pkt. 
Co-administration of EVOTAZ with glecaprevir/pibrentasvir fixed dose combination is contraindicated because of the potential increase in the risk of ALT elevations due to a significant increase in glecaprevir and pibrentasvir plasma concentrations (see section 4.3).
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver filmovertrukket tablet indeholder 300 mg atazanavir (som sulfat) og 150 mg cobicistat. 
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 300 mg of atazanavir (as sulphate) and 150 mg of cobicistat.
Samtidig administration af EVOTAZ og protonpumpehæmmere (PPI'er) frarådes på grund af nedsat opløselighed af atazanavir, da den intragastriske pH stiger med protonpumpehæmmere (se pkt. 
Co-administration of EVOTAZ with proton pump inhibitors (PPIs) is not recommended due to the decreased solubility of atazanavir as intra-gastric pH increase with PPIs (see section 4.5).
Cobicistat har vist sig at nedsætte estimeret kreatininclearance på grund af hæmningen af tubulær kreatininudskillelse. 
Cobicistat has been shown to decrease estimated creatinine clearance due to inhibition of tubular secretion of creatinine.
Der er ikke set signifikant påvirkning af methadon-koncentrationen ved samtidig administration af atazanavir. 
No significant effect on methadone concentrations was observed when co-administered with atazanavir.
Samtidig behandling med EVOTAZ og andre proteasehæmmere frarådes. 
Co-administration of EVOTAZ with other protease inhibitors is not recommended.
CYP3A4-substrater eller UGT1A1-isoformen af UDP-glucuronyltransferase og som har et smalt terapeutisk vindue: alfuzosin (alpha-1-adrenoreceptor antagonist) amiodaron, bepridil, dronedaron, quinidin, systemisk lidocain (antiarytmika/midler mod angina pectoris) astemizol, terfenadin (antihistaminer) cisaprid (gastrointestinalt motilitetsfremmende middel) ergotaminderivater (f.eks. dihydroergotamin, ergometrin, ergotamin, methylergonovin) pimozid, quetiapin, lurasidon (antipsykotika/neuroleptika) (se pkt. 
substrates of CYP3A4 or the UGT1A1 isoform of UDP-glucuronyltransferase and have narrow therapeutic windows: alfuzosin (alpha-1-adrenoreceptor antagonist) amiodarone, bepridil, dronedarone, quinidine, systemic lidocaine (antiarrhythmics/antianginals) astemizole, terfenadine (antihistamines) cisapride (gastrointestinal motility agent) ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine) pimozide, quetiapine, lurasidone (antipsychotics/neuroleptics) (see section 4.5) ticagrelor (platelet aggregation inhibitor) triazolam, midazolam administered orally (sedatives/hypnotics) (for caution on parenterally administered midazolam, see section 4.5).
Manglende data i tidsvinduet men får studielægemiddel aUge 48-vindue er fra dag 309 til 378 (inklusive) b Uge 144-vindue er fra dag 967 til 1.050 (inklusive) c Omfatter forsøgspersoner, som havde ≥50 kopier/ml i uge 48- eller 144-vinduet, forsøgspersoner, som afbrød behandlingen tidligt som følge af manglende eller svigtende virkning, forsøgspersoner, som afbrød behandlingen af andre årsager end en bivirkning, død eller manglende eller svigtende virkning, og som på tidspunktet for seponering havde en viral load på ≥50 kopier/ml. 
c Includes subjects who had ≥50 copies/ml in the week 48 or 144 windows, subjects who discontinued early due to lack or loss of efficacy, subjects who discontinued for reasons other than an adverse event, death or lack or loss of efficacy and at the time of discontinuation had a viral value of ≥50 copies/ml.
Tenofovirdisoproxilfumarat (tenofovir DF) 300 mg 1 gang dagligt (atazanavir 400 mg 1 gang dagligt) 
Tenofovir disoproxil fumarate (tenofovir DF) 300 mg once daily (atazanavir 400 mg once daily)
Raltegravir 400 mg to gange dagligt (atazanavir 400 mg) 
Raltegravir 400 mg twice daily (atazanavir 400 mg)
Samtidig administration af EVOTAZ og cisaprid er kontraindiceret (se pkt. 
Co-administration of EVOTAZ and cisapride is contraindicated (see section 4.3).
Dosisjustering er ikke nødvendig for telaprevir ved samtidig administration af EVOTAZ. 
No dose adjustment is required for telaprevir if co-administered with EVOTAZ.
Samtidig administration af EVOTAZ og CYP3A-hæmmende lægemidler kan nedsætte clearance af atazanavir og cobicistat, hvilket medfører øgede plasmakoncentrationer af atazanavir og cobicistat (se pkt. 
Co-administration of EVOTAZ with medicinal products that inhibit CYP3A may decrease the clearance of atazanavir and cobicistat, resulting in increased atazanavir and cobicistat plasma concentrations (see section 4.5).
Samtidig administration af EVOTAZ og astemizol og terfenadin er kontraindiceret (se pkt. 
Co-administration of EVOTAZ with astemizole and terfenadine is contraindicated (see section 4.3).
hverken ketoconazol eller itraconazol. 
available for co-administration of EVOTAZ with either ketoconazole or itraconazole.
EVOTAZ bør ikke administreres sammen med triazolam eller oralt administreret midazolam (se pkt. 
EVOTAZ should not be co-administered with triazolam or orally administered midazolam (see section 4.3), whereas caution should be used with co-administration of EVOTAZ and parenteral midazolam.
ANTIMYKOBAKTERIELLE MIDLER 
ANTIMYCOBACTERIALS
Gruppen med atazanavir og cobicistat var sammenlignelig med gruppen med atazanavir og ritonavir med hensyn til demografiske karakteristika og karakteristika ved baseline. 
The demographic and baseline characteristics were similar between the atazanavir with cobicistat and atazanavir with ritonavir groups.
Kombinationen af avanafil og EVOTAZ er kontraindiceret (se pkt. 
The combination of avanafil and EVOTAZ is contraindicated (see section 4.3).
Samtidig administration af EVOTAZ og rivaroxaban bør undgås. 
Avoid concomitant use of EVOTAZ and rivaroxaban.
Samtidig administration af salmeterol og EVOTAZ frarådes (se pkt. 
Co-administration of salmeterol with EVOTAZ is not recommended (see section 4.4).
Cobicistat er en kraftig mekanisme-baseret CYP3A-hæmmer og en svag CYP2D6-hæmmer. 
Cobicistat is a strong mechanism-based CYP3A inhibitor and a weak CYP2D6 inhibitor.
Omeprazol 40 mg 1 gang dagligt (atazanavir 400 mg 1 gang dagligt, 2 timer efter omeprazol) 
Omeprazole 40 mg once daily (atazanavir 400 mg once daily, 2 hours after omeprazole)
Der er ikke set signifikant effekt på koncentrationen af lamivudin eller zidovudin ved samtidig administration med atazanavir. 
No significant effect on lamivudine and zidovudine concentrations was observed when co-administered with atazanavir.
Koncentrationen af disse immunsuppressiva kan øges ved samtidig administration af EVOTAZ. 
Concentrations of these immunosuppressants may be increased when co-administered with EVOTAZ.
Der er rapporteret nephrolithiasis hos patienter behandlet med atazanavir (se pkt. 
Nephrolithiasis has been reported in patients receiving atazanavir (see section 4.8).
Hvis du har taget for meget EVOTAZ 
If you take more EVOTAZ than you should
astemizol eller terfenadin (bruges almindeligvis til at behandle allergiske symptomer, det er medicin som muligvis kan fås uden recept); cisaprid (bruges til at behandle tilbageløb af maveindhold, nogle gange kaldt sure opstød); pimozid (bruges til at behandle skizofreni); amiodaron; dronedaron; quinidin; lidocain (som injektion) eller bepridil (bruges til at korrigere hjerterytmen); ergotamin; dihydroergotamin; ergonovin; ergometrin og methylergonovin (bruges til at behandle migræne); og alfuzosin (bruges til at behandle forstørret blærehalskirtel (prostata)) quetiapin (bruges til at behandle skizofreni, bipolar lidelse (manio-depressiv sygdom) og moderat til svær depression); lurasidon (bruges til at behandle skizofreni) medicin, der indeholder perikon (Hypericum perforatum, et naturlægemiddel). 
carbamazepine, phenobarbital and phenytoin (antiepileptics used to prevent seizures) astemizole or terfenadine (commonly used to treat allergy symptoms, these medicines may be available without prescription); cisapride (used to treat gastric reflux, sometimes called heartburn); pimozide (used to treat schizophrenia); amiodarone, dronedarone, quinidine, lidocaine (injectable) or bepridil (used to correct heart rhythm); ergotamine, dihydroergotamine, ergonovine, ergometrine and methylergonovine (used to treat headaches); and alfuzosin (used to treat enlarged prostatic gland) quetiapine (used to treat schizophrenia, bipolar disorder and major depressive disorder); lurasidone (used to treat schizophrenia) medicines containing St. John's wort (Hypericum perforatum, a herbal preparation).
Samtidig administration med EVOTAZ forventes at øge dolutegravir plasmakoncentrationerne. 
Co-administration with EVOTAZ is expected to increase dolutegravir plasma concentrations.
Interaktionsmekanismen er cobicistats P-gp-hæmning. 
The mechanism of interaction is inhibition of P-gp by cobicistat.
Interaktionsmekanismen er atazanavirs UGT1A1-hæmning. 
The mechanism of interaction is inhibition of UGT1A1 by atazanavir.
Koncentrationen af atazanavir med eller uden cobicistat forventes at øges hos patienter med moderat eller svær nedsat leverfunktion (se pkt. 
Concentrations of atazanavir given with cobicistat are expected to be increased in patients with impaired hepatic function (see sections 4.2 and 4.4).
Koncentrationen af disse lægemidler kan øges ved samtidig administration af EVOTAZ. 
Concentrations of these medicinal products may be increased when co-administered with EVOTAZ.
Samtidig administration af bepridil er kontraindiceret (se pkt. 
Co-administration with bepridil is contraindicated (see section 4.3).
Efter et fedtrigt måltid faldt Cmax og AUC med henholdsvis 36% og 25% sammenlignet med efter et let måltid. 
Cmax and AUCs after a high fat meal decreased 36% and 25% in comparison to a light meal, respectively; however, the 24-hour atazanavir concentration was similar when EVOTAZ was given with a light meal and a high fat meal.
Plasmakoncentrationerne af drospirenon forhøjes efter administration af drospirenon/ethinylestradiol med atazanavir/cobicistat. 
Plasma concentrations of drospirenone are increased following administration of drospirenone/ethinyloestradiol with atazanavir/cobicistat.
Telaprevir 750 mg tre gange dagligt (atazanavir/ritonavir 300/100 mg 1 gang dagligt) 
Telaprevir 750 mg three times daily (atazanavir/ritonavir 300/100 mg once daily)
Dihydroergotamin Ergometrin Ergotamin Methylergonovin 
Dihydroergotamine Ergometrine Ergotamine Methylergonovine
Tabletkerne - mikrokrystallinsk cellulose (E460(i)), croscarmellosenatrium (E468), natriumstivlesesglycolat, crospovidon (E1202), stearinsyre (E570), magnesiumstearat (E470b), hydroxypropylcellulose (E463), silica (E551) 
Tablet core - microcrystalline cellulose (E460(i)), croscarmellose sodium (E468), sodium starch glycolate, crospovidone (E1202), stearic acid (E570), magnesium stearate (E470b), hydroxypropyl cellulose (E463), silicon dioxide (E551) Film-coating - hypromellose (hydroxypropyl methyl cellulose, E464), titanium dioxide (E171), talc (E553b), triacetin (E1518), red iron oxide (E172)
Clarithromycin 500 mg to gange dagligt (atazanavir 400 mg 1 gang dagligt) 
ANTIBIOTICS Clarithromycin 500 mg twice daily (atazanavir 400 mg once daily)
Interaktionsmekanismen er etravirins CYP3A4-induktion. 
The mechanism of interaction is CYP3A4 induction by etravirine.
Interaktionsmekanismen er atazanavirs, cobicistats og ketoconazols eller itraconazols CYP3A4-hæmning. 
The mechanism of interaction is CYP3A4 inhibition by atazanavir, cobicistat and ketoconazole or itraconazole.
Rosuvastatin (10 mg enkeltdosis) (atazanavir 300 mg 1 gang dagligt med cobicistat 150 mg 1 gang dagligt) 
Rosuvastatin (10 mg single dose) (atazanavir 300 mg once daily with cobicistat 150 mg once daily)
Samtidig administration af tenofoviralafenamid og cobicistat forventes at øge plasmakoncentrationerne af tenofoviralafenamid og tenofovir. 
Co-administration of tenofovir alafenamide with cobicistat is expected to increase tenofovir alafenamide and tenofovir plasma concentrations.
Plasmakoncentrationerne af digoxin kan øges ved samtidig administration af EVOTAZ. 
Plasma concentrations of digoxin may be increased when co-administered with EVOTAZ.
disopyramid, flecainid, mexiletin, propafenon, digoxin, bosentan, amlodipin, felodipin, nicardipin, nifedipin, verapamil, diltiazem, metoprolol og timolol (medicin til at sænke blodtrykket og til at nedsætte eller korrigere hjerterytmen (pulsen)) atorvastatin, pravastatin, fluvastatin, pitavastatin og rosuvastatin (bruges til at sænke kolesterolindholdet i blodet) salmeterol (bruges til at behandle astma) ciclosporin, tacrolimus og sirolimus (medicin, der anvendes til at svække kroppens immunsystem) visse antibiotika (rifabutin, clarithromycin) ketoconazol, itraconazol, voriconazol og fluconazol (svampemidler) metformin (bruges til at behandle type 2-sukkersyge) warfarin, rivaroxaban og dabigatran (blodfortyndende midler, anvendes til at mindske risikoen for blodpropper) irinotecan, dasatinib, nilotinib, vinblastin og vincristin (bruges til at behandle kræft) trazodon (bruges til at behandle depression) perphenazin, risperidon, thioridazin, midazolam (givet som injektion), buspiron, clorazepat, diazepam, estazolam, flurazepam og zolpidem (anvendes til at behandle lidelser i nervesystemet) buprenorphin (anvendes mod smerter og til at behandle opioidafhængighed) 
It is especially important to mention these: medicines containing ritonavir or cobicistat (booster agents) other medicines to treat HIV infection (e.g. indinavir, didanosine, tenofovir disoproxil, tenofovir alafenamide, efavirenz, etravirine, nevirapine and maraviroc) boceprevir, simeprevir and sofosbuvir/velpatasvir/voxilaprevir (used to treat hepatitis C) sildenafil, vardenafil and tadalafil (used by men to treat impotence [erectile dysfunction]) if you are taking an oral contraceptive ("the Pill") any medicines used to treat diseases related to the acid in the stomach (e.g. antacids, H2-blockers like famotidine and proton pump inhibitors like omeprazole) disopyramide, flecainide, mexiletine, propafenone, digoxin, bosentan, amlodipine, felodipine, nicardipine, nifedipine, verapamil, diltiazem, metoprolol and timolol (medicines to lower blood pressure, to slow heart rate or to correct heart rhythm) atorvastatin, pravastatin, fluvastatin, pitavastatin and rosuvastatin (used to lower blood cholesterol) salmeterol (used to treat asthma) ciclosporin, tacrolimus and sirolimus (medicines to decrease the effects of body's immune system) certain antibiotics (rifabutin, clarithromycin) ketoconazole, itraconazole, voriconazole and fluconazole (antifungals) metformin (used to treat type 2 diabetes) warfarin, rivaroxaban and dabigatran (anticoagulants, used to reduce blood clots) irinotecan, dasatinib, nilotinib, vinblastine and vincristine (used to treat cancer) trazodone (used to treat depression)
EVOTAZ 300 mg/150 mg filmovertrukne tabletter 2. 
NAME OF THE MEDICINAL PRODUCT EVOTAZ 300 mg/150 mg film-coated tablets
EVOTAZ tages oralt sammen med føde (se pkt. 
EVOTAZ is to be taken orally with food (see section 5.2).
Galdesten er blevet rapporteret hos patienter, der har taget atazanavir (et af indholsstofferne i EVOTAZ). 
Gall stones have been reported in patients taking atazanavir, a component of EVOTAZ.
Didanosin (enterokapsler) 400 mg som enkeltdosis (atazanavir 400 mg 1 gang dagligt) 
Didanosine (enteric coated capsules) 400 mg single dose (atazanavir 400 mg once daily)
Perikon (Hypericum perforatum) Samtidig brug af perikon og EVOTAZ kan forventes at medføre signifikant fald i atazanavirs og cobicistats plasmaniveauer. 
Concomitant use of St. John's wort with EVOTAZ may be expected to result in significant reduction in plasma levels of cobicistat and atazanavir.
Interaktionsmekanismen er atazanavirs og cobicistats P-gp-hæmning. 
The mechanism of interaction is P-gp inhibition by atazanavir and cobicistat.
300 mg/pibrentasvir 120 mg 1 gang dagligt (atazanavir 300 mg med ritonavir 100 mg 1 gang dagligt*) 
Glecaprevir 300 mg/pibrentasvir 120 mg once daily (atazanavir 300 mg with ritonavir 100 mg once daily*)
Koncentrationer af disse antiarytmika kan øges ved samtidig administration af EVOTAZ. 
Concentrations of these antiarrhythmics may be increased when co-administered with EVOTAZ.
Kontraception 
Contraception requirements
Colchicin plasmakoncentrationerne kan øges ved samtidig administration af EVOTAZ. 
Colchicine plasma concentrations may be increased when co-administered with EVOTAZ.
Samtidig administration af EVOTAZ og disse ergotaminderivater er kontraindiceret (se pkt. 
Co-administration of EVOTAZ and these ergot derivates is contraindicated (see section 4.3).
Interaktionsmekanismen er atazanavirs og/eller cobicistats CYP3A4- og/eller CYP2D6-hæmning. 
The mechanism of interaction is inhibition of CYP3A4 and/or CYP2D6 by atazanavir and/or cobicistat.
Tenofoviralafenamid 10 mg 1 gang dagligt/emtricitabin 200 mg 1 gang dagligt (atazanavir 300 mg 1 gang dagligt og cobicistat 150 mg 1 gang dagligt) 
Tenofovir alafenamide 10 mg once daily/emtricitabine 200 mg once daily (atazanavir 300 mg once daily with cobicistat 150 mg once daily)
Samtidig administration af EVOTAZ og indinavir frarådes (se pkt. 
Co-administration of EVOTAZ and indinavir is not recommended (see section 4.4).
Interaktionsmekanismen er nevirapins CYP3A4-induktion og atazanavirs og cobicistats CYP3A4-hæmning. 
The mechanism of interaction is CYP3A4 induction by nevirapine and CYP3A4 inhibition by atazanavir and cobicistat.
Samtidig administration af EVOTAZ og alfuzosin er kontraindiceret (se pkt. 
Co-administration of EVOTAZ with alfuzosin is contraindicated (see section 4.3)
Lamivudin 150 mg 2 gange dagligt + zidovudin 300 mg 2 gange dagligt (atazanavir 400 mg 1 gang dagligt) 
Lamivudine 150 mg twice daily + zidovudine 300 mg twice daily (atazanavir 400 mg once daily)
Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer) livstruende uregelmæssige hjerteslag (puls) (torsades de pointes) overfølsomhed (allergisk reaktion) manglende appetit, vægttab, vægtstigning depression, angst, søvnforstyrrelser desorientering, hukommelsestab (amnesi) følelsesløshed, svaghed, prikken eller smerter i arme og ben (perifer neuropati) besvimelse (synkope), højt blodtryk (hypertension) åndenød betændelse i bugspytkirtlen (pankreatitis), irritation af slimhinden i mavesækken (gastritis), sår i munden og forkølelsessår leverbetændelse (hepatitis) angioødem (voldsom hævelse af hud og andre steder, som oftest læber og øjne) nældefeber (kløende udslæt), hårtab eller -udtynding (alopeci), kløe (pruritus) svind af muskelmasse (atrofi), ledsmerter (artralgi), muskelsmerter (myalgi) 
Uncommon (may affect up to 1 in 100 people) torsade de pointes (life threatening irregular heart beat) hypersensitivity (allergic reaction) anorexia (loss of appetite), weight loss, weight gain depression, anxiety, sleep disorder disorientation, amnesia (loss of memory) peripheral neuropathy (numbness, weakness, tingling or pain in the arms and legs) syncope (fainting), hypertension (high blood pressure) dyspnoea (shortness of breath) pancreatitis (inflammation of the pancreas), gastritis (inflammation of the stomach), stomatitis aphthous (mouth ulcers and cold sores) hepatitis (inflammation of the liver) angioedema (severe swelling of the skin and other tissues most often the lips or the eyes) urticaria (itchy rash), alopecia (unusual hair loss or thinning), pruritus (itching) muscle atrophy (muscle shrinkage), arthralgia (joint pain), myalgia (aching muscles) nephrolithiasis (formation of kidney stones), interstitial nephritis (kidney inflammation), hematuria (blood in the urine), proteinuria (excess protein in the urine), pollakiuria (increased frequency of urination), chronic kidney disease (how well your kidneys work) gynaecomastia (breast enlargement in men) chest pain, malaise (generally feeling unwell), fever asthenia (unusual tiredness or weakness) serious skin rashes (allergic reactions including rash, a high temperature, increased levels of liver enzymes seen in blood tests, an increase in a type of white blood cell [esosinophilia] and/or enlarged lymph nodes) (see section 2) gallbladder disorders (gallstones and gallbladder inflammation)
Knogler, led, muskler og bindevæv ikke almindelig myalgi, muskelatrofi, artralgi sjælden myopati 
Adverse Reactions uncommon myalgia, muscle atrophy, arthralgia rare myopathy